In Switzerland, marketing authorisation and insurance coverage can have different boundaries. A medicine may be approved for a treatment while compulsory health insurance pays only under narrower conditions. Checking the details before the first supply can prevent unwelcome financial surprises.
Identify the product and purpose first
Swissmedic assesses medicines for authorisation in Switzerland. For payment by compulsory health insurance, the Federal Office of Public Health’s Specialities List also matters. Its reimbursement restrictions can be narrower than the authorised use.
Ask for the exact product and the intended purpose: treating type 2 diabetes or managing weight. The ingredient name alone is insufficient. A European authorisation is not automatically a Swiss authorisation and does not replace a Swiss coverage assessment.
What changed for Mounjaro in 2026
The FOPH publishes a new listing for type 2 diabetes and an extension of reimbursement restrictions for weight management, effective from 1 January 2026. The blanket claim that Mounjaro is absent from the Specialities List is therefore outdated. The published restrictions run until the end of 2027.
For weight management, the documents include prior insurer approval, accompanying care and specialist provision, among other requirements. They also specify monitoring criteria. A BMI figure alone cannot establish your entitlement: the other conditions and the current version have to be considered together.
Why funding approval is different from a prescription
Prior insurer approval concerns payment for the circumstances described in the application. A prescription records the treatment prescribed. Ask the practice whether advance approval is needed, who submits the application and which medical records must support it.
Request an understandable summary: Which product and period are covered? What reviews are expected? When is another assessment needed? Keep the written response. A verbal assumption or another insured person’s experience is not a substitute for checking your own arrangement.
Check the current restrictions together
The FOPH also publishes specific restrictions for Wegovy, with separate rules for adults and adolescents. Such documents may have an expiry date or be amended later. An old table on an advice website is therefore an unreliable basis for your next pharmacy visit.
The linked FOPH decisions establish the changes described, but do not guarantee that no later amendment has occurred. Your personal coverage enquiry depends on the SL restriction currently in force. Ask your practice or pharmacy to verify it. Reimbursement limits should not be mistaken for general medical contraindications.
What you may still need to pay
Whether a medicine is eligible for reimbursement is different from the amount on your own bill. Check the deductible, cost sharing and any separately charged services against your insurance circumstances. Request figures in Swiss francs and a clear statement of the period they cover.
Include consultations, follow-up and agreed nutritional counselling in your planning. If self-funding, obtain a current quotation and discuss whether ongoing costs are manageable. Prices in older FOPH publications should not be turned into a supposedly current monthly private-treatment bill.
Common questions
Does EU approval mean I can obtain the medicine in Switzerland?
No. Swissmedic authorisation and the national presentation actually available are what matter in Switzerland. A pharmacy can check a specific supply request. European news about tablets establishes neither Swiss availability nor Swiss reimbursement.
What if the insurer asks for more documents?
Request an exact list and pass it to the treating practice. Arrange the decision, application and medical evidence by date. Ask what any stated deadline means, rather than repeatedly sending an incomplete application or assuming approval has already been granted.
Sources & further reading
- BAG: Veröffentlichungen zur Spezialitätenliste
- BAG: Spezialitätenliste
- BAG: Mounjaro, Limitation zur Gewichtsregulierung ab 01.01.2026
- BAG: Mounjaro, Neuaufnahme bei Typ-2-Diabetes ab 01.01.2026
- Swissmedic: Mounjaro, Indikationserweiterung Gewichtsregulierung
- BAG: Leistungen bei Arzneimitteln
Sources checked:
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact